Now Sanofi’s diabetes drug “Toujeo” Was Approved By FDA
Sanofi’s diabetes drug Toujeo has been approved by FDA, this is a more potent follow-up to the French drugmaker’s best selling insulin product Lantus. Sanofi’s diabetes drug Toujeo is long-acting basal insulin to treat adults with both type 1 and type 2 diabetes.
This medicine is considered among the most important in Sanofi’s pipeline. The company is expected to try to convert patients from Lantus to Toujeo as fast as possible, with the older drug about to lose U.S. patent protection.
In addition gaining Toujeo patients through conversions, “there’s about a million new patients for basal insulin each and every year,” said Joe Balzer, head of U.S. commercial operations for Toujeo, which is awaiting a European approval decision.
Toujeo has the same active ingredient as Lantus, called insulin glargine, but at three times the concentration and with a design to release the insulin more gradually. The medicine provides similar blood glucose control as Lantus with significantly lower rates of hypoglycemia, a potentially dangerous drop in blood sugar.
Lantus, the world’s most prescribed insulin with sales of $7.2 billion in 2014, accounts for more than 30 percent of Sanofi profit. Warnings of faltering U.S. Lantus sales contributed to the sudden sacking of Sanofi Chief Executive Officer Chris Viehbacher last year.
The company has yet to announce a Toujeo price and declined to discuss any discounting strategy aimed at gaining reimbursement from insurers and other payers.
“We are confident of Toujeo achieving a position on payer formularies,” said Andrew Purcell, head of Sanofi’s U.S. diabetes business.
Nowaday there are more than 370 million people worldwide have diabetes. About 90 – 95% have type 2, which is normally lead to obesity and significantly increase the risk of many serious health issues. Mostly type 2 diabetes patients start with a variety of other medicines to control blood sugar, and yeah! 100% of them require insulin.